StockData

Korsana Biosciences vs Ovid Therapeutics

KRSA and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRSA and OVID compare

Ovid Therapeutics is the larger company, worth 2.8 times as much as Korsana Biosciences ($434M against $152M).

Korsana Biosciences grew revenue faster over the last twelve months (−12.6% versus −76.2% for Ovid Therapeutics).

Korsana Biosciences keeps more of each dollar of sales as profit, with a net margin of −353% compared with −2179% at Ovid Therapeutics.

Ovid Therapeutics scores higher on the StockData Score (10 against 6 for Korsana Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRSAOVID
Size and price
Market cap$152M$434M
Share price$32.50$2.22
Change, 1 year241%70.1%
Change, 5 years−90.5%−31.9%
Beta (5Y)5.731.34
Employees123
StockData Score
Total score610 (better)
Valuation score01 (better)
Growth score11
Performance score12 (better)
Health score46 (better)
Dividend score00
Valuation
P/S80.1× (better)274×
P/B29.9×2.1× (better)
Fair value$5.48–
Margin of safety−493%–
Growth
Revenue growth (TTM)−12.6% (better)−76.2%
Revenue growth, 5Y average−2.0% (better)−10.5%
Profitability
Operating margin−359% (better)−3687%
Net margin−353% (better)−2179%
Return on equity−98.2%−26.0% (better)
Return on invested capital−116% (better)−160%
Financial health
Debt / equity0.000.00
Current ratio0.8212.39 (better)
Altman Z-score−9.259.41 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions15.1%75.3%
Held by insiders–13.6%
Insider net buying, 12 months–−$29.3K
Short interest, % of float–10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.